Therapeutic implications of b-raf mutations ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Therapeutic implications of b-raf mutations in colorectal cancer
Auteur(s) :
Lebrun, H. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Turpin, Anthony [Auteur]
Service d'oncologie médicale (CHRU Lille)
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Zerbib, P. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Turpin, Anthony [Auteur]
Service d'oncologie médicale (CHRU Lille)
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Zerbib, P. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Titre de la revue :
Journal of visceral surgery
Nom court de la revue :
J Visc Surg
Date de publication :
2021-05-08
ISSN :
1878-7886
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Colorectal cancers (CRC) with B-RAF mutation carry a particularly poor prognosis. In this context, the value of first-line intensified chemotherapy associated with an anti-VEGF (Vascular endothelial growth factor) to treat ...
Lire la suite >Colorectal cancers (CRC) with B-RAF mutation carry a particularly poor prognosis. In this context, the value of first-line intensified chemotherapy associated with an anti-VEGF (Vascular endothelial growth factor) to treat metastatic CRC has recently been called into question. In patients with mutated B-RAF, the efficacy of first-line anti-EGFR (Epidermal Growth Factor Receptor) associated with chemotherapy for treatment of metastatic CRC is uncertain while that of anti-VEGF has been shown to be effective. The therapeutic pathways involving inhibition of B-RAF activity, although ineffective as monotherapy, have received marketing authorization when used in association with anti-EGFR for second-line treatment of metastatic CRC. Immunotherapy has provided very encouraging results in a recent phase III study in patients with microsatellite instability, irrespective of their B-RAF status. Finally, new therapies, targeting other RAF proteins and other specific receptors are currently under development. Surgery for liver metastases in patients with the B-RAF mutation should be considered whenever possible, after a complete search for peritoneal carcinomatosis and distant metastases, similarly to workup for patients without the B-RAF mutation.Lire moins >
Lire la suite >Colorectal cancers (CRC) with B-RAF mutation carry a particularly poor prognosis. In this context, the value of first-line intensified chemotherapy associated with an anti-VEGF (Vascular endothelial growth factor) to treat metastatic CRC has recently been called into question. In patients with mutated B-RAF, the efficacy of first-line anti-EGFR (Epidermal Growth Factor Receptor) associated with chemotherapy for treatment of metastatic CRC is uncertain while that of anti-VEGF has been shown to be effective. The therapeutic pathways involving inhibition of B-RAF activity, although ineffective as monotherapy, have received marketing authorization when used in association with anti-EGFR for second-line treatment of metastatic CRC. Immunotherapy has provided very encouraging results in a recent phase III study in patients with microsatellite instability, irrespective of their B-RAF status. Finally, new therapies, targeting other RAF proteins and other specific receptors are currently under development. Surgery for liver metastases in patients with the B-RAF mutation should be considered whenever possible, after a complete search for peritoneal carcinomatosis and distant metastases, similarly to workup for patients without the B-RAF mutation.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CNRS
Université de Lille
Université de Lille
Collections :
Date de dépôt :
2021-07-06T12:44:21Z
2024-02-05T16:15:54Z
2024-02-05T16:15:54Z